Seagen touts full PhII Tukysa data as it plots colorectal cancer expansion
As rumors of a Merck buyout continue to swirl around Seagen, the big Seattle biotech is charging ahead with new data for its cancer drug Tukysa.
Seagen reported full results Saturday from a Phase II study measuring Tukysa’s effectiveness in second-line HER2-positive metastatic colorectal cancer, after revealing a 38.1% overall response rate in May. The new data show Tukysa, in combination with Herceptin, induced a progression-free survival of 8.2 months and overall survival of 24.1 months.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.